your market intelligence analyst
Search Results
99 results
Your search is now limited to «Company News in Immune System Diseases» expert search.
Business Wire 07/23/2019 16:00
The data were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) being held in Mexico City.
More from Business Wire:
Johnson & Johnson 07/23/2019 11:00
About Johnson & Johnson At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress.
More from Johnson & Johnson:
STAT 07/23/2019 10:59
An experimental HIV drug from Merck — if effective — could be fashioned into an implant given annually to prevent patients at high risk from contracting the virus.
More from STAT:
BioPharma Dive 07/23/2019 09:10
While presenting second quarter earnings Tuesday, executives detailed how the biotech is widening its focus to include ophthalmology and immunology, supported respectively by the recent acquisition of Nightstar Therapeutics and Biogen's two experimental lupus treatments.
More from BioPharma Dive:
ENDPOINTS 07/22/2019 09:00
Gilead, a leader in the HIV sector, is paying a modest $25 million in cash for the right to jump on the platform at Durect, which has been using its technology to come up with an extended-release version of bupivacaine ...
More from ENDPOINTS:
PR Newswire 07/22/2019 08:00
Gilead also received exclusive access to the SABER® platform for HIV and Hepatitis B Virus (HBV) and the exclusive option to license additional SABER-based products directed to HIV and HBV.
More from PR Newswire:
Channel NewsAsia (Singapore) 07/12/2019 11:20
World Johnson & Johnson said on Friday it plans to conduct a late-stage study of its investigational vaccine for Human Immunodeficiency Virus (HIV) in several countries across the Americas and Europe, including the United States.
More from Channel NewsAsia (Singapore):
CNBC - Business 07/12/2019 10:34
Pharmaceutical giant Gilead Sciences, which dominates the $26 billion-a-year HIV drug market, reached an agreement with the Trump administration to donate medications that reduce the risk of HIV transmission for up to 200,000 people a year until 2025 ...
More from CNBC - Business:
FiercePharmaManufacturing 07/10/2019 10:22
Gilead’s and ViiV’s HIV new-to-brand market shares were “very stable” in the second quarter, Credit Suisse analysts said in a recent investor note.
More from FiercePharmaManufacturing:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications